公开(公告)号：US20190388428A1

公开(公告)日：2019-12-26

申请号：US16478704

申请日：2018-01-18

Applicant: NOVARTIS AG

Inventor： Miloud Achour ,  Brumo Galli ,  Edgar John ,  Michael Juhnke ,  Dragutin Knezic ,  Vishal Shamji Koradia ,  Rita Ramos

IPC: A61K31/5355 ,  A61K31/496 ,  A61K9/48 ,  A61K47/26 ,  A61K47/38

Abstract: The present invention relates to a pharmaceutical composition comprising an oxazine derivative BACE-1 inhibitor, a process for the preparation thereof, and its use in the treatment or prevention of Alzheimer's disease.

公开(公告)号：US09623012B2

公开(公告)日：2017-04-18

申请号：US14770819

申请日：2014-02-26

Applicant: Novartis AG

Inventor： Miloud Achour ,  Robin Alec Fairhurst ,  Arnaud Grandeury ,  Shinji Hatakeyama ,  Magdalena Koziczak-Holbro ,  Nicola Tufilli ,  Thomas Ullrich

IPC: A61K31/428 ,  A61K31/19 ,  A61K9/00 ,  A61K9/20 ,  A61K9/48

CPC classification number: A61K31/428 ,  A61K9/0053 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/485 ,  A61K9/4858 ,  A61K9/4866 ,  A61K31/19

Abstract: The present invention relates to a pharmaceutical composition in solid oral dosage form comprising (R)-7-(2-(1-(4-butoxyphenyl)-2-methylpropan-2-ylamino)-1-hydroxyethyl)-5-hydroxybenzo[d]thiazol-2(3H)-one acetate salt.